Evidence, Guidelines, and Gut Checks: Musings on Entering the Post-Statin Era of Lipid Management
DOI: 10.1016/J.CJCA.2015.07.006
关键词: Guideline 、 Disease management (health) 、 Intensive care medicine 、 Kidney disease 、 Lipid management 、 Proprotein convertase 、 Statin 、 Medicine 、 Dyslipidemia 、 Kexin
摘要: This viewpoint describes the results of a survey administered to 55 physicians who are key opinion leader experts in dyslipidemia management and thoroughly knowledgeable about current guidelines emerging therapies. The purpose was determine level low density lipoprotein-cholesterol (LDL-C) achieved with maximally tolerated statin monotherapy that would trigger preference by most for use soon be available proprotein convertase subtilisin/kexin type 9 inhibitor as next add-on agent. Because suggest uniform LDL-C goal when treating patients meeting guideline indications therapy, it expected size gap between attained statins uniformly dictate inhibitors desired. expectation, however, not met. In particular, primary prevention chronic kidney disease do appear represent high priority circumstances achieving even despite existing guidelines. Implications future post-statin era discussed.
onlinecjc.ca
elsevier.com参考文章(10)
Robert P. Giugliano, Marc S. Sabatine, Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? Journal of the American College of Cardiology. ,vol. 65, pp. 2638- 2651 ,(2015) , 10.1016/J.JACC.2015.05.001
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema, Gaetano M De Ferrari, Witold Ruzyllo, Paul De Lucca, KyungAh Im, Erin A Bohula, Craig Reist, Stephen D Wiviott, Andrew M Tershakovec, Thomas A Musliner, Eugene Braunwald, Robert M Califf, None, Ezetimibe added to statin therapy after acute coronary syndromes The New England Journal of Medicine. ,vol. 372, pp. 2387- 2397 ,(2015) , 10.1056/NEJMOA1410489
Bertram Pitt, GB John Mancini, Stephen G Ellis, Howard S Rosman, Jong-Soon Park, Mark E Mcgovern, PLAC I Investigators, Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events Journal of the American College of Cardiology. ,vol. 26, pp. 1133- 1139 ,(1995) , 10.1016/0735-1097(95)00301-0
Jennifer G Robinson, Michel Farnier, Michel Krempf, Jean Bergeron, Gérald Luc, Maurizio Averna, Erik S Stroes, Gisle Langslet, Frederick J Raal, Mahfouz El Shahawy, Michael J Koren, Norman E Lepor, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, John JP Kastelein, None, Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events The New England Journal of Medicine. ,vol. 372, pp. 1489- 1499 ,(2015) , 10.1056/NEJMOA1501031
Neil J Stone, Jennifer G Robinson, Alice H Lichtenstein, C Noel Bairey Merz, Conrad B Blum, Robert H Eckel, Anne C Goldberg, David Gordon, Daniel Levy, Donald M Lloyd-Jones, Patrick McBride, J Sanford Schwartz, Susan T Shero, Sidney C Smith Jr, Karol Watson, Peter WF Wilson, None, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation. ,vol. 129, pp. 2889- 2934 ,(2014) , 10.1161/01.CIR.0000437738.63853.7A
Eliano Pio Navarese, Michalina Kolodziejczak, Volker Schulze, Paul A. Gurbel, Udaya Tantry, Yingfeng Lin, Maximilian Brockmeyer, David E. Kandzari, Julia M. Kubica, Ralph B. D'Agostino, Jacek Kubica, Massimo Volpe, Stefan Agewall, Dean J. Kereiakes, Malte Kelm, Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia Annals of Internal Medicine. ,vol. 163, pp. 40- 51 ,(2015) , 10.7326/M14-2957
Todd J. Anderson, Jean Grégoire, Robert A. Hegele, Patrick Couture, G.B. John Mancini, Ruth McPherson, Gordon A. Francis, Paul Poirier, David C. Lau, Steven Grover, Jacques Genest, André C. Carpentier, Robert Dufour, Milan Gupta, Richard Ward, Lawrence A. Leiter, Eva Lonn, Dominic S. Ng, Glen J. Pearson, Gillian M. Yates, James A. Stone, Ehud Ur, 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult Canadian Journal of Cardiology. ,vol. 29, pp. 151- 167 ,(2013) , 10.1016/J.CJCA.2012.11.032
Dominic S. Ng, Glen J. Pearson, Gillian M. Yates, James A. Stone, Ehud Ur, Todd J. Anderson, Jean Grégoire, Robert A. Hegele, Patrick Couture, G.B. John Mancini, Ruth McPherson, Gordon A. Francis, Paul Poirier, David C. Lau, Steven Grover, Jacques Genest, André C. Carpentier, Robert Dufour, Milan Gupta, Richard Ward, Lawrence A. Leiter, Eva Lonn, Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel Canadian Journal of Cardiology. ,vol. 30, pp. 377- 380 ,(2014) , 10.1016/J.CJCA.2014.01.009
Michael J. Koren, Robert P. Giugliano, Frederick J. Raal, David Sullivan, Michael Bolognese, Gisle Langslet, Fernando Civeira, Ransi Somaratne, Patric Nelson, Thomas Liu, Rob Scott, Scott M. Wasserman, Marc S. Sabatine, Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial Circulation. ,vol. 129, pp. 234- 243 ,(2014) , 10.1161/CIRCULATIONAHA.113.007012
Colin Baigent, Martin J Landray, Christina Reith, Jonathan Emberson, David C Wheeler, Charles Tomson, Christoph Wanner, Vera Krane, Alan Cass, Jonathan Craig, Bruce Neal, Lixin Jiang, Lai Seong Hooi, Adeera Levin, Lawrence Agodoa, Mike Gaziano, Bertram Kasiske, Robert Walker, Ziad A Massy, Bo Feldt-Rasmussen, Udom Krairittichai, Vuddidhej Ophascharoensuk, Bengt Fellström, Hallvard Holdaas, Vladimir Tesar, Andrzej Wiecek, Diederick Grobbee, Dick De Zeeuw, Carola Grönhagen-Riska, Tanaji Dasgupta, David Lewis, William Herrington, Marion Mafham, William Majoni, Karl Wallendszus, Richard Grimm, Terje Pedersen, Jonathan Tobert, Jane Armitage, Alex Baxter, Christopher Bray, Yiping Chen, Zhengming Chen, Michael Hill, Carol Knott, Sarah Parish, David Simpson, Peter Sleight, Alan Young, Rory Collins, None, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial The Lancet. ,vol. 377, pp. 2181- 2192 ,(2011) , 10.1016/S0140-6736(11)60739-3